The Russian company Aluron has started certification of the production of genetic research reagents at its new plant in Serpukhov, the press service of the Ministry of Investment, Industry and Science of the Moscow Region reported. The products, which will replace imported reagents, are intended for early diagnosis of diseases and pre-pregnancy screening for potential parents. The investments in the projects have already reached 250 million rubles.
“The company has already launched the certification process for the manufacturing of reagents as medical devices and is preparing to launch production later this year,” said Ekaterina Zinovieva, Deputy Prime Minister and Minister of Investment, Industry and Science of the Moscow Region.
Aluron plans to produce reagents based on domestic developments within the framework of contract production, and later, it will develop its own products.
The launch of reagent production is only the first stage of an investment project for the high-tech production of domestic innovative medical devices. As Oleg Andrukh, CEO of Aluron, noted, the company also plans to master the production of components for medical equipment and build a pharmaceutical production of lyophilizates.
The development of medical and pharmaceutical production is one of the priorities of the Moscow Region. In March 2025, the Government of the Russian Federation approved a decree prepared by the Ministry of Economic Development on the creation of the Bolshoy Serpukhov special economic zone of industrial and production type in the region.
It was reported that the creation of the SEZ will create almost 900 jobs. Investors are interested in launching the production of medicines, developing a system for disinfection and sterilization of medical devices, as well as creating domestic equipment for DNA research.
